H.C. Wainwright Reiterates Their Buy Rating on Urogen Pharma (URGN)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGNResearch Report) today and set a price target of $75.00. The company’s shares closed last Monday at $30.78.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -7.2% and a 37.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Urogen Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $52.80, which is a 70.8% upside from current levels. In a report issued on November 12, Cowen & Co. also assigned a Buy rating to the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $55.49 and a one-year low of $20.72. Currently, Urogen Pharma has an average volume of 249.8K.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of URGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.